Biotechnology Value Fund LP
11/21/2024 | Press release | Distributed by Public on 11/21/2024 19:28
Beneficial Ownership Report - Form SC 13G
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
SCHEDULE 13G
(Rule 13d-102)
INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT
TO RULES 13d-1(b), (c), AND (d) AND AMENDMENTS THERETO FILED
PURSUANT TO RULE 13d-2(b)
(Amendment No. )1
|
iTeos Therapeutics, Inc. |
|
(Name of Issuer) |
|
Common Stock, $0.001 par value per share |
|
(Title of Class of Securities) |
|
46565G104 |
|
(CUSIP Number) |
|
November 14, 2024 |
|
(Date of Event Which Requires Filing of this Statement) |
Check the appropriate box to designate the rule pursuant to which this Schedule is filed:
| ☐ | Rule 13d-1(b) |
| ☒ | Rule 13d-1(c) |
| ☐ | Rule 13d-1(d) |
1 The remainder of this cover page shall be filled out for a reporting person's initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter disclosures provided in a prior cover page.
The information required on the remainder of this cover page shall not be deemed to be "filed" for the purpose of Section 18 of the Securities Exchange Act of 1934 ("Act") or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).
CUSIP No. 46565G104
| 1 | NAME OF REPORTING PERSON | |||||
| Biotechnology Value Fund, L.P. | ||||||
| 2 | CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP | (a) ☒ | ||||
| (b) ☐ | ||||||
| 3 | SEC USE ONLY | |||||
| 4 | CITIZENSHIP OR PLACE OF ORGANIZATION | |||||
| Delaware | ||||||
| NUMBER OF | 5 | SOLE VOTING POWER | ||||
| SHARES | ||||||
| BENEFICIALLY | 0 | |||||
| OWNED BY | 6 | SHARED VOTING POWER | ||||
| EACH | ||||||
| REPORTING | 1,194,335 | |||||
| PERSON WITH | 7 | SOLE DISPOSITIVE POWER | ||||
| 0 | ||||||
| 8 | SHARED DISPOSITIVE POWER | |||||
| 1,194,335 | ||||||
| 9 | AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON | |||||
| 1,194,335 | ||||||
| 10 | CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES | ☐ | ||||
| 11 | PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9) | |||||
| 3.3% | ||||||
| 12 | TYPE OF REPORTING PERSON | |||||
| PN |
| 2 |
CUSIP No. 46565G104
| 1 | NAME OF REPORTING PERSON | |||||
| BVF I GP LLC | ||||||
| 2 | CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP | (a) ☒ | ||||
| (b) ☐ | ||||||
| 3 | SEC USE ONLY | |||||
| 4 | CITIZENSHIP OR PLACE OF ORGANIZATION | |||||
| Delaware | ||||||
| NUMBER OF | 5 | SOLE VOTING POWER | ||||
| SHARES | ||||||
| BENEFICIALLY | 0 | |||||
| OWNED BY | 6 | SHARED VOTING POWER | ||||
| EACH | ||||||
| REPORTING | 1,194,335 | |||||
| PERSON WITH | 7 | SOLE DISPOSITIVE POWER | ||||
| 0 | ||||||
| 8 | SHARED DISPOSITIVE POWER | |||||
| 1,194,335 | ||||||
| 9 | AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON | |||||
| 1,194,335 | ||||||
| 10 | CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES | ☐ | ||||
| 11 | PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9) | |||||
| 3.3% | ||||||
| 12 | TYPE OF REPORTING PERSON | |||||
| OO |
| 3 |
CUSIP No. 46565G104
| 1 | NAME OF REPORTING PERSON | |||||
| Biotechnology Value Fund II, L.P. | ||||||
| 2 | CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP | (a) ☒ | ||||
| (b) ☐ | ||||||
| 3 | SEC USE ONLY | |||||
| 4 | CITIZENSHIP OR PLACE OF ORGANIZATION | |||||
| Delaware | ||||||
| NUMBER OF | 5 | SOLE VOTING POWER | ||||
| SHARES | ||||||
| BENEFICIALLY | 0 | |||||
| OWNED BY | 6 | SHARED VOTING POWER | ||||
| EACH | ||||||
| REPORTING | 964,115 | |||||
| PERSON WITH | 7 | SOLE DISPOSITIVE POWER | ||||
| 0 | ||||||
| 8 | SHARED DISPOSITIVE POWER | |||||
| 964,115 | ||||||
| 9 | AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON | |||||
| 964,115 | ||||||
| 10 | CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES | ☐ | ||||
| 11 | PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9) | |||||
| 2.6% | ||||||
| 12 | TYPE OF REPORTING PERSON | |||||
| PN |
| 4 |
CUSIP No. 46565G104
| 1 | NAME OF REPORTING PERSON | |||||
| BVF II GP LLC | ||||||
| 2 | CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP | (a) ☒ | ||||
| (b) ☐ | ||||||
| 3 | SEC USE ONLY | |||||
| 4 | CITIZENSHIP OR PLACE OF ORGANIZATION | |||||
| Delaware | ||||||
| NUMBER OF | 5 | SOLE VOTING POWER | ||||
| SHARES | ||||||
| BENEFICIALLY | 0 | |||||
| OWNED BY | 6 | SHARED VOTING POWER | ||||
| EACH | ||||||
| REPORTING | 964,115 | |||||
| PERSON WITH | 7 | SOLE DISPOSITIVE POWER | ||||
| 0 | ||||||
| 8 | SHARED DISPOSITIVE POWER | |||||
| 964,115 | ||||||
| 9 | AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON | |||||
| 964,115 | ||||||
| 10 | CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES | ☐ | ||||
| 11 | PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9) | |||||
| 2.6% | ||||||
| 12 | TYPE OF REPORTING PERSON | |||||
| OO |
| 5 |
CUSIP No. 46565G104
| 1 | NAME OF REPORTING PERSON | |||||
| Biotechnology Value Trading Fund OS LP | ||||||
| 2 | CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP | (a) ☒ | ||||
| (b) ☐ | ||||||
| 3 | SEC USE ONLY | |||||
| 4 | CITIZENSHIP OR PLACE OF ORGANIZATION | |||||
| Cayman Islands | ||||||
| NUMBER OF | 5 | SOLE VOTING POWER | ||||
| SHARES | ||||||
| BENEFICIALLY | 0 | |||||
| OWNED BY | 6 | SHARED VOTING POWER | ||||
| EACH | ||||||
| REPORTING | 121,152 | |||||
| PERSON WITH | 7 | SOLE DISPOSITIVE POWER | ||||
| 0 | ||||||
| 8 | SHARED DISPOSITIVE POWER | |||||
| 121,152 | ||||||
| 9 | AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON | |||||
| 121,152 | ||||||
| 10 | CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES | ☐ | ||||
| 11 | PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9) | |||||
| Less than 1% | ||||||
| 12 | TYPE OF REPORTING PERSON | |||||
| PN |
| 6 |
CUSIP No. 46565G104
| 1 | NAME OF REPORTING PERSON | |||||
| BVF Partners OS Ltd. | ||||||
| 2 | CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP | (a) ☒ | ||||
| (b) ☐ | ||||||
| 3 | SEC USE ONLY | |||||
| 4 | CITIZENSHIP OR PLACE OF ORGANIZATION | |||||
| Cayman Islands | ||||||
| NUMBER OF | 5 | SOLE VOTING POWER | ||||
| SHARES | ||||||
| BENEFICIALLY | 0 | |||||
| OWNED BY | 6 | SHARED VOTING POWER | ||||
| EACH | ||||||
| REPORTING | 121,152 | |||||
| PERSON WITH | 7 | SOLE DISPOSITIVE POWER | ||||
| 0 | ||||||
| 8 | SHARED DISPOSITIVE POWER | |||||
| 121,152 | ||||||
| 9 | AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON | |||||
| 121,152 | ||||||
| 10 | CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES | ☐ | ||||
| 11 | PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9) | |||||
| Less than 1% | ||||||
| 12 | TYPE OF REPORTING PERSON | |||||
| CO |
| 7 |
CUSIP No. 46565G104
| 1 | NAME OF REPORTING PERSON | |||||
| BVF GP Holdings LLC | ||||||
| 2 | CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP | (a) ☒ | ||||
| (b) ☐ | ||||||
| 3 | SEC USE ONLY | |||||
| 4 | CITIZENSHIP OR PLACE OF ORGANIZATION | |||||
| Delaware | ||||||
| NUMBER OF | 5 | SOLE VOTING POWER | ||||
| SHARES | ||||||
| BENEFICIALLY | 0 | |||||
| OWNED BY | 6 | SHARED VOTING POWER | ||||
| EACH | ||||||
| REPORTING | 2,158,450 | |||||
| PERSON WITH | 7 | SOLE DISPOSITIVE POWER | ||||
| 0 | ||||||
| 8 | SHARED DISPOSITIVE POWER | |||||
| 2,158,450 | ||||||
| 9 | AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON | |||||
| 2,158,450 | ||||||
| 10 | CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES | ☐ | ||||
| 11 | PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9) | |||||
| 5.9% | ||||||
| 12 | TYPE OF REPORTING PERSON | |||||
| OO |
| 8 |
CUSIP No. 46565G104
| 1 | NAME OF REPORTING PERSON | |||||
| BVF Partners L.P. | ||||||
| 2 | CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP | (a) ☒ | ||||
| (b) ☐ | ||||||
| 3 | SEC USE ONLY | |||||
| 4 | CITIZENSHIP OR PLACE OF ORGANIZATION | |||||
| Delaware | ||||||
| NUMBER OF | 5 | SOLE VOTING POWER | ||||
| SHARES | ||||||
| BENEFICIALLY | 0 | |||||
| OWNED BY | 6 | SHARED VOTING POWER | ||||
| EACH | ||||||
| REPORTING | 2,325,000 | |||||
| PERSON WITH | 7 | SOLE DISPOSITIVE POWER | ||||
| 0 | ||||||
| 8 | SHARED DISPOSITIVE POWER | |||||
| 2,325,000 | ||||||
| 9 | AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON | |||||
| 2,325,000 | ||||||
| 10 | CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES | ☐ | ||||
| 11 | PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9) | |||||
| 6.4% | ||||||
| 12 | TYPE OF REPORTING PERSON | |||||
| PN, IA |
| 9 |
CUSIP No. 46565G104
| 1 | NAME OF REPORTING PERSON | |||||
| BVF Inc. | ||||||
| 2 | CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP | (a) ☒ | ||||
| (b) ☐ | ||||||
| 3 | SEC USE ONLY | |||||
| 4 | CITIZENSHIP OR PLACE OF ORGANIZATION | |||||
| Delaware | ||||||
| NUMBER OF | 5 | SOLE VOTING POWER | ||||
| SHARES | ||||||
| BENEFICIALLY | 0 | |||||
| OWNED BY | 6 | SHARED VOTING POWER | ||||
| EACH | ||||||
| REPORTING | 2,325,000 | |||||
| PERSON WITH | 7 | SOLE DISPOSITIVE POWER | ||||
| 0 | ||||||
| 8 | SHARED DISPOSITIVE POWER | |||||
| 2,325,000 | ||||||
| 9 | AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON | |||||
| 2,325,000 | ||||||
| 10 | CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES | ☐ | ||||
| 11 | PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9) | |||||
| 6.4% | ||||||
| 12 | TYPE OF REPORTING PERSON | |||||
| CO |
| 10 |
CUSIP No. 46565G104
| 1 | NAME OF REPORTING PERSON | |||||
| Mark N. Lampert | ||||||
| 2 | CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP | (a) ☒ | ||||
| (b) ☐ | ||||||
| 3 | SEC USE ONLY | |||||
| 4 | CITIZENSHIP OR PLACE OF ORGANIZATION | |||||
| United States | ||||||
| NUMBER OF | 5 | SOLE VOTING POWER | ||||
| SHARES | ||||||
| BENEFICIALLY | 0 | |||||
| OWNED BY | 6 | SHARED VOTING POWER | ||||
| EACH | ||||||
| REPORTING | 2,325,000 | |||||
| PERSON WITH | 7 | SOLE DISPOSITIVE POWER | ||||
| 0 | ||||||
| 8 | SHARED DISPOSITIVE POWER | |||||
| 2,325,000 | ||||||
| 9 | AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON | |||||
| 2,325,000 | ||||||
| 10 | CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES | ☐ | ||||
| 11 | PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9) | |||||
| 6.4% | ||||||
| 12 | TYPE OF REPORTING PERSON | |||||
| IN |
| 11 |
CUSIP No. 46565G104
| Item 1(a). | Name of Issuer: |
iTeos Therapeutics, Inc., a Delaware corporation (the "Issuer").
| Item 1(b). | Address of Issuer's Principal Executive Offices: |
321 Arsenal St.
Watertown, Massachusetts 02472
| Item 2(a). | Name of Person Filing |
| Item 2(b). | Address of Principal Business Office or, if None, Residence |
| Item 2(c). | Citizenship |
Biotechnology Value Fund, L.P. ("BVF")
44 Montgomery St., 40th Floor
San Francisco, California 94104
Citizenship: Delaware
BVF I GP LLC ("BVF GP")
44 Montgomery St., 40th Floor
San Francisco, California 94104
Citizenship: Delaware
Biotechnology Value Fund II, L.P. ("BVF2")
44 Montgomery St., 40th Floor
San Francisco, California 94104
Citizenship: Delaware
BVF II GP LLC ("BVF2 GP")
44 Montgomery St., 40th Floor
San Francisco, California 94104
Citizenship: Delaware
Biotechnology Value Trading Fund OS LP ("Trading Fund OS")
PO Box 309 Ugland House
Grand Cayman, KY1-1104
Cayman Islands
Citizenship: Cayman Islands
BVF Partners OS Ltd. ("Partners OS")
PO Box 309 Ugland House
Grand Cayman, KY1-1104
Cayman Islands
Citizenship: Cayman Islands
BVF GP Holdings LLC ("BVF GPH")
44 Montgomery St., 40th Floor
San Francisco, California 94104
Citizenship: Delaware
| 12 |
CUSIP No. 46565G104
BVF Partners L.P. ("Partners")
44 Montgomery St., 40th Floor
San Francisco, California 94104
Citizenship: Delaware
BVF Inc.
44 Montgomery St., 40th Floor
San Francisco, California 94104
Citizenship: Delaware
Mark N. Lampert ("Mr. Lampert")
44 Montgomery St., 40th Floor
San Francisco, California 94104
Citizenship: United States
Each of the foregoing is referred to as a "Reporting Person" and collectively as the "Reporting Persons."
| Item 2(d). | Title of Class of Securities: |
Common Stock, par value $0.001 per share (the "Shares").
| Item 2(e). | CUSIP Number: |
46565G104
| Item 3. | If This Statement is Filed Pursuant to Rule 13d-1(b), or 13d-2(b) or (c), Check Whether the Person Filing is a: |
| /x/ | Not applicable. | ||
| (a) | / / | Broker or dealer registered under Section 15 of the Exchange Act. | |
| (b) | / / | Bank as defined in Section 3(a)(6) of the Exchange Act. | |
| (c) | / / | Insurance company as defined in Section 3(a)(19) of the Exchange Act. | |
| (d) | / / | Investment company registered under Section 8 of the Investment Company Act. | |
| (e) | / / | An investment adviser in accordance with Rule 13d-1(b)(1)(ii)(E). | |
| (f) | / / | An employee benefit plan or endowment fund in accordance with Rule 13d-1(b)(1)(ii)(F). | |
| (g) | / / | A parent holding company or control person in accordance with Rule 13d-1(b)(1)(ii)(G). | |
| (h) | / / | A savings association as defined in Section 3(b) of the Federal Deposit Insurance Act. | |
| (i) | / / | A church plan that is excluded from the definition of an investment company under Section 3(c)(14) of the Investment Company Act. | |
| (j) | / / | A non-U.S. institution, in accordance with Rule 13d-1(b)(1)(ii)(J). | |
| (k) | / / | Group, in accordance with Rule 13d-1(b)(1)(ii)(K). If filing as a non-U.S. institution in accordance with Rule 13d-1(b)(1)(ii)(J), please specify the type of institution: ____ |
| 13 |
CUSIP No. 46565G104
| Item 4. | Ownership |
| (a) | Amount beneficially owned: |
As of the close of business on November 21, 2024, (i) BVF beneficially owned 1,194,335 Shares, (ii) BVF2 beneficially owned 964,115 Shares, and (iii) Trading Fund OS beneficially owned 121,152 Shares.
BVF GP, as the general partner of BVF, may be deemed to beneficially own the 1,194,335 Shares beneficially owned by BVF.
BVF2 GP, as the general partner of BVF2, may be deemed to beneficially own the 964,115 Shares beneficially owned by BVF2.
Partners OS, as the general partner of Trading Fund OS, may be deemed to beneficially own the 121,152 Shares beneficially owned by Trading Fund OS.
BVF GPH, as the sole member of each of BVF GP and BVF2 GP, may be deemed to beneficially own the 2,158,450 Shares beneficially owned in the aggregate by BVF and BVF2.
Partners, as the investment manager of BVF, BVF2 and Trading Fund OS, and the sole member of Partners OS, may be deemed to beneficially own the 2,325,000 Shares beneficially owned in the aggregate by BVF, BVF2 and Trading Fund OS and held in a certain Partners managed account (the "Partners Managed Account"), including 45,398 Shares held in the Partners Managed Account.
BVF Inc., as the general partner of Partners, may be deemed to beneficially own the 2,325,000 Shares beneficially owned by Partners.
Mr. Lampert, as a director and officer of BVF Inc., may be deemed to beneficially own the 2,325,000 Shares beneficially owned by BVF Inc.
The foregoing should not be construed in and of itself as an admission by any Reporting Person as to beneficial ownership of any Shares owned by another Reporting Person. BVF GP disclaims beneficial ownership of the Shares beneficially owned by BVF. BVF2 GP disclaims beneficial ownership of the Shares beneficially owned by BVF2. Partners OS disclaims beneficial ownership of the Shares beneficially owned by Trading Fund OS. BVF GPH disclaims beneficial ownership of the Shares beneficially owned by BVF and BVF2. Each of Partners, BVF Inc. and Mr. Lampert disclaims beneficial ownership of the Shares beneficially owned by BVF, BVF2 and Trading Fund OS and held in the Partners Managed Account, and the filing of this statement shall not be construed as an admission that any such person or entity is the beneficial owner of any such securities.
| 14 |
CUSIP No. 46565G104
| (b) | Percent of class: |
The following percentages are based on 36,533,918 Shares outstanding as of November 7, 2024, as reported in the Issuer's Quarterly Report on Form 10-Q filed with the Securities and Exchange Commission on November 12, 2024.
As of the close of business on November 21, 2024, (i) BVF beneficially owned approximately 3.3% of the outstanding Shares, (ii) BVF2 beneficially owned approximately 2.6% of the outstanding Shares, (iii) Trading Fund OS beneficially owned less than 1% of the outstanding Shares, (iv) BVF GP may be deemed to beneficially own approximately 3.3% of the outstanding Shares, (v) BVF2 GP may be deemed to beneficially own approximately 2.6% of the outstanding Shares, (vi) Partners OS may be deemed to beneficially own less than 1% of the outstanding Shares, (vii) BVF GPH may be deemed to beneficially own approximately 5.9% of the outstanding Shares, and (viii) each of Partners, BVF Inc. and Mr. Lampert may be deemed to beneficially own approximately 6.4% of the outstanding Shares (less than 1% of the outstanding Shares are held in the Partners Managed Account).
| (c) | Number of shares as to which such person has: |
| (i) | Sole power to vote or to direct the vote |
See Cover Pages Items 5-9.
| (ii) | Shared power to vote or to direct the vote |
See Cover Pages Items 5-9.
| (iii) | Sole power to dispose or to direct the disposition of |
See Cover Pages Items 5-9.
| (iv) | Shared power to dispose or to direct the disposition of |
See Cover Pages Items 5-9.
| Item 5. | Ownership of Five Percent or Less of a Class. |
Not Applicable.
| Item 6. | Ownership of More than Five Percent on Behalf of Another Person. |
BVF GPH, Partners, BVF Inc. and Mr. Lampert share voting and dispositive power over the Shares beneficially owned by BVF and BVF2. Partners, BVF Inc. and Mr. Lampert share voting and dispositive power over the Shares beneficially owned by Trading Fund OS and held in the Partners Managed Account.
| 15 |
CUSIP No. 46565G104
| Item 7. | Identification and Classification of the Subsidiary That Acquired the Security Being Reported on by the Parent Holding Company or Control Person. |
Not Applicable.
| Item 8. | Identification and Classification of Members of the Group. |
See Exhibit 99.1.
| Item 9. | Notice of Dissolution of Group. |
Not Applicable.
| Item 10. | Certifications. |
By signing below each of the undersigned certifies that, to the best of its knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect.
| 16 |
CUSIP No. 46565G104
SIGNATURE
After reasonable inquiry and to the best of his knowledge and belief, each of the undersigned certifies that the information set forth in this statement is true, complete and correct.
Dated: November 21, 2024
| BIOTECHNOLOGY VALUE FUND, L.P. | BIOTECHNOLOGY VALUE TRADING FUND OS LP | |||
| By: | BVF I GP LLC, its general partner | By: | BVF Partners L.P., its investment manager | |
| By: | BVF Inc., its general partner | |||
| By: |
/s/ Mark N. Lampert |
|||
| Mark N. Lampert | By: | /s/ Mark N. Lampert | ||
| Chief Executive Officer | Mark N. Lampert | |||
| President | ||||
| BVF I GP LLC | ||||
| BVF GP HOLDINGS LLC | ||||
| By: | /s/ Mark N. Lampert | |||
| Mark N. Lampert | By: | /s/ Mark N. Lampert | ||
| Chief Executive Officer | Mark N. Lampert | |||
| Chief Executive Officer | ||||
| BIOTECHNOLOGY VALUE FUND II, L.P. | ||||
| BVF PARTNERS L.P. | ||||
| By: | BVF II GP LLC, its general partner | |||
| By: | BVF Inc., its general partner | |||
| By: |
/s/ Mark N. Lampert |
|||
| Mark N. Lampert | By: | /s/ Mark N. Lampert | ||
| Chief Executive Officer | Mark N. Lampert | |||
| President | ||||
| BVF II GP LLC | ||||
| BVF INC. | ||||
| By: | /s/ Mark N. Lampert | |||
| Mark N. Lampert | By: | /s/ Mark N. Lampert | ||
| Chief Executive Officer | Mark N. Lampert | |||
| President | ||||
| BVF PARTNERS OS LTD. | ||||
| /s/ Mark N. Lampert | ||||
| By: | BVF Partners L.P., its sole member | MARK N. LAMPERT | ||
| By: | BVF Inc., its general partner | |||
| By: |
/s/ Mark N. Lampert |
|||
| Mark N. Lampert | ||||
| President |
| 17 |